BOSTON COMMERCE LIMITED is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (1) | (7) |
| margin % | — | (284.3) | (1361.1) |
| Owners' profit | (0) | (1) | (7) |
| EPS, as reported (₹) | (0.20) | 0.78 | 10.25 |
| ROE % · ROCE % | (2.2) · (2.1) | (9.3) · (5.2) | 564.4 · (856.6) |
| Debt / equity (x) | 0.13 | 0.92 | (1.30) |
| Cash from operations | 0 | (5) | 4 |
| Capex | 0 | 0 | 0 |
| ₹ crore | Q4 FY24 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | (0) | (0) | 0 | 0 | (0) | (7) |
| Net profit | (0) | (0) | (0) | (0) | 0 | 0 | (0) | (7) |
| EPS (₹) | (0.20) | (0.01) | (0.07) | 0.70 | 0.06 | 0.06 | 0.02 | 10.34 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Letter to shareholders regarding 31st AGM and FY26 Annual Report | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Book closure notice for 31st AGM from September 24 to 30, 2026 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Annual Report and AGM Notice submitted for FY 2025-26 | results | high | — | — |
| 11 Sept 2026 · Board appoints Co-Statutory Auditor Nirav S Shah and Co, fixes AGM on Sep 30 | management changes | medium | — | — |
| 11 Sept 2026 · Board approves FY26 audited results, auditor changes; AGM on Sept 30 | board shareholder meetings | medium | — | — |
| 21 Aug 2026 · Boston Commerce cancels board meet to approve Q1 results | results | medium | — | — |
| 14 Aug 2026 · New CFO and Whole-Time Director appointed at Boston Commerce | management changes | high | — | — |
| 14 Aug 2026 · Board reshuffle and postponement of June-quarter results | board shareholder meetings | low | — | — |
| 12 Aug 2026 · MD and CFO resign on the same day at Boston Commerce | management changes | high | — | — |
| 12 Aug 2026 · CFO Kunjan Rathod resigns from Boston Commerce effective August 12, 2026 | management changes | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 0.5 | 23.2 | 1 of 29 | 100% |
| ROCE | (933.7) | 6.1 | 29 of 29 | 0% |
| ROE | 564.4 | 7.3 | 1 of 26 | 100% |
| Debt / Equity | (1.3) | 0.0 | 2 of 26 | 96% |
| Revenue growth | (100.0) | 20.8 | 25 of 25 | 0% |
| Profit growth | (1376.3) | 22.0 | 25 of 25 | 0% |
| Market cap | 3 | 38 | 30 of 30 | 0% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
